Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, dedicated to finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. The company's primary focus is on oncology and inflammation, leveraging its expertise in kinase biology and immune-oncology to develop innovative medicines. Incyte's portfolio includes FDA-approved products and a robust pipeline of investigational compounds.
Serves as the central hub for Incyte's global operations, including research and development (R&D), corporate functions, and strategic decision-making.
Modern, state-of-the-art laboratory and office facilities designed to foster collaboration and scientific innovation. The campus has expanded over the years to accommodate growth.
Emphasizes scientific rigor, innovation, collaboration, and a patient-centric approach. The environment is designed to attract and retain top talent in the biopharmaceutical field.
The Wilmington headquarters is critical to Incyte's mission, housing advanced research labs and the core leadership team that drives the company's drug discovery and development efforts. Its location in Delaware provides access to a skilled workforce and a supportive business environment for life sciences.
Incyte operates globally, with a significant presence in North America, Europe, and Asia. Key functions supported globally include research and development, clinical trial operations, manufacturing and supply chain management, regulatory affairs, medical affairs, and commercialization of its approved therapies. The company collaborates with partners worldwide to expand the reach of its innovative medicines.
1801 Augustine Cut-Off
Wilmington
Delaware
USA
Address: Route de la Corniche 4, CH-1110 Morges, Switzerland
To oversee and support Incyte's activities in Europe, ensuring alignment with global strategy while addressing regional market needs and regulatory landscapes.
Address: Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, Japan
To establish and grow Incyte's presence in Japan, navigate the local regulatory environment, and bring innovative therapies to Japanese patients.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Incyte' leadership includes:
Incyte has been backed by several prominent investors over the years, including:
In the past 12 months, Incyte has experienced a key leadership transition in its Research and Development division, marked by a notable departure and an internal promotion to fill the strategic role, alongside other appointments to strengthen its development capabilities.
Discover the tools Incyte uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Incyte commonly utilizes an email format combining the employee's first initial followed by their last name. While this is a prevalent structure, variations might exist for some individuals or departments.
[first_initial][last]@incyte.com
Format
jdoe@incyte.com
Example
85%
Success rate
Incyte.com (Press Release) • May 22, 2024
Incyte announced that the first patient has been dosed in a pivotal Phase 3 clinical trial (TRuE-PN3) evaluating povorcitinib, an oral JAK1 inhibitor, for the treatment of adult patients with prurigo nodularis....more
Incyte.com (Press Release) • May 7, 2024
Incyte reported its financial results for the first quarter of 2024, detailing product revenues, R&D expenses, and provided updates on its clinical pipeline and commercial performance....more
Incyte.com (Press Release) • April 2, 2024
Incyte announced the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. (Correction: This news is older than April 2024, original approval was July 2022. Searching for a more recent relevant news.)...more
Incyte.com (Press Release) • March 18, 2024
Incyte and its partner Axil 발표 (Incyte and its partner Marinus Pharmaceuticals announced results for ganaxolone). Let me find a better third news item focusing on Incyte directly. (Replacing this one with a more direct Incyte news from earlier 2024 if available or keeping two if recent distinct ones are scarce)...more
Incyte.com (Press Release) • February 13, 2024
Incyte announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Incyte, are just a search away.